If you are wondering whether Daiichi Sankyo Company is starting to look like a bargain or still has room to fall, you are not alone; this stock has quietly shifted from market favorite to value ...

The antibody-drug conjugate (ADC) market is emerging as one of the most competitive areas in pharma, with companies such as AstraZeneca, Gilead and Pfizer investing billions into the space. Amid the ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be in the works from Korea’s Alteogen following a licensing deal worth up to ...

Daiichi Sankyo Company (TSE:4568) has been making the rounds among investor circles lately, with some wondering what’s next for this well-known name in pharmaceuticals. Although there haven’t been any ...

Masahiro Kato takes over as Managing Director, Oliver Appelhans appointed to Head of the European Specialty Business Unit MUNICH--(BUSINESS WIRE)--Today, Daiichi Sankyo Europe GmbH, the European ...

Daiichi Sankyo is leading the world in the development of antibody-drug conjugates, which are finally paying off in cancer after more than a decade of ups and downs. The company stands poised to ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the ...

Hiroyuki Okuzawa will step into the role starting in April. Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sunao Manabe, DVM, ...

Pharmaceutical company Daiichi Sankyo Inc. is consolidating its New Jersey facilities in a new U.S. headquarters in Basking Ridge, it announced Monday.Daiichi Sankyo, the U.S. subsidiary of global ...